StockNews.AI
SNTI
StockNews.AI
5 days

Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

1. Senti Bio will present at a biotech webinar on August 19, 2025. 2. CEO Timothy Lu will discuss their Gene Circuit platform. 3. Senti Bio focuses on innovative cell and gene therapies. 4. Company aims to improve cancer treatment precision and control. 5. They are advancing their Gene Circuits beyond oncology applications.

6m saved
Insight
Article

FAQ

Why Bullish?

The presentation could attract investor interest in innovative biotech solutions, similar to prior successful company webinars. Historical examples show that successful investor presentations often correlate with stock price increases, especially for biotech firms with promising technologies.

How important is it?

This event highlights Senti Bio's innovative approaches, likely improving visibility and investor confidence. Increased awareness around their Gene Circuit technology can position SNTI favorably within the biotech sector.

Why Short Term?

The upcoming webinar may generate immediate investor interest, as seen with other biotech presentations that prompted quick market reactions. Historically, news within 1-2 weeks post-presentation leads to short-term price movements.

Related Companies

NVCRCRISEDITBMRNALNY
Live video webcast on Tuesday, August 19th at 2:20 PM ET August 14, 2025 09:15 ET  | Source: Senti Biosciences, Inc. SOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025. Details for the presentation are as follows: Date/Time: Tuesday, August 19, 2025 at 2:20 PM ET Presenter: Timothy Lu, M.D., Ph.D., Senti Bio’s Co-Founder and Chief Executive OfficerRegistration Link: HERE About Webull Financial Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology. With low-cost trading on a wide range of assets, advanced charting tools, and real-time market data, Webull is revolutionizing the way individuals approach investing. The user-centric approach and commitment to staying at the forefront of industry trends underscore the mission to provide a seamless and rewarding experience for traders of all levels. Through the Webull Group, Webull Financial and its affiliates combine to serve tens of millions of users from over 180 countries worldwide. Securities and futures trading is offered to customers by Webull Financial LLC ("Webull Financial"), a broker-dealer registered with the Securities and Exchange Commission (SEC) and a futures commission merchant registered with the Commodity Futures Trading Commission (CFTC). Webull Financial is a member of the Financial Industry Authority (FINRA), the National Futures Association (NFA), and the Securities Investor Protection Corporation (SIPC). All investing is subject to risk, including the possible loss of principal. For more information about Webull, visit www.webull.com. About Senti Bio Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company’s wholly-owned pipeline is comprised of cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti’s Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships. Availability of Other Information About Senti Biosciences, Inc.For more information, please visit the Senti Bio website at www.sentibio.com or follow Senti Bio on X (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website (www.sentibio.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. Investor Contact:JTC Team, LLCJenene Thomas(908) 824-0775SNTI@jtcir.com

Related News